Illumina CFO Predicts GWAS Market Will Return to 'Normal State' in 2010

Despite experiencing "some weakness" in demand for its whole-genome genotyping chips in recent quarters, Illumina expects the genome-wide association studies market to revive by the middle of next year, and believes its array business will continue to grow, driven by the agricultural biotechnology market and custom projects.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.